1. A method for preparing guargum-based microparticles encapsulating Mebeverine hydrochloride for targeted drug delivery to the colon.

2. The method of claim 1, where the microparticles are prepared using an emulsion dehydration technique.

3. The method of claim 1 or 2, wherein the drug-to-polymer ratio in the microparticles is optimized for maximal encapsulation efficiency and controlled drug release.

4. A pharmaceutical composition comprising guargum-based microparticles encapsulating Mebeverine hydrochloride for oral administration.

5. The pharmaceutical composition of claim 4, wherein the microparticles release Mebeverine hydrochloride specifically in the colon.

6. The use of guargum as a carrier material in the preparation of microparticles for targeted drug delivery of Mebeverine hydrochloride.

7. A method for treating irritable bowel syndrome comprising administering an effective amount of the pharmaceutical composition of claim 4 to a patient in need thereof.

8. The method of claim 1, wherein the stirring speed and concentration of Span 80 are optimized during the preparation of the microparticles.

9. The pharmaceutical composition of claim 4, wherein the microparticles are characterized by a controlled drug release profile, ensuring the therapeutic efficacy of Mebeverine hydrochloride while minimizing systemic side effects.

10. A method for improving the oral bioavailability of Mebeverine hydrochloride in the treatment of irritable bowel syndrome, comprising administering the pharmaceutical composition of claim 4 to a patient.

Description:[001] The field of invention in your manuscript relates to the development of guargum-based microparticles for the targeted delivery of Mebeverine hydrochloride, a drug used to treat irritable bowel syndrome (IBS). This innovative approach involves the use of natural polysaccharides, specifically guargum, to achieve site-specific and controlled drug release in the colon.
[002] The study focuses on understanding the impact of various process variables like drug-to-polymer ratio, stirring speed, and the presence of Span 80 on the optimization of these formulations. The aim is to enhance the oral bioavailability of the drug and ensure its absorption specifically in the colon, thereby improving therapeutic outcomes for patients with IBS.
BACKGROUND OF THE INVENTION
[003] The following description provides the information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[004] Further, the approaches described in this section are approaches that could be pursued, but not necessarily approaches that have been previously conceived or pursued. Therefore, unless otherwise indicated, it should not be assumed that any of the approaches described in this section qualify as prior art merely by virtue of their inclusion in this section.
[005] The background of the proposed invention in your manuscript revolves around the development of a colon-specific drug delivery system using guargum-based microparticles for the controlled release of Mebeverine hydrochloride. This approach is intended to treat irritable bowel syndrome (IBS), a condition characterized by abnormal gut motility and smooth muscle spasms.
[006] Mebeverine hydrochloride, a musculotropic antispasmodic drug, lacks site-specific delivery when administered orally, necessitating higher doses to achieve therapeutic efficacy. The proposed delivery system aims to overcome this limitation by targeting the drug directly to the colon, which offers several physiological advantages for drug release and absorption, such as prolonged transit time, higher enzymatic activity, and a relatively neutral pH environment.
[007] The invention involves preparing microparticles using the emulsion dehydration method, with guargum as the carrier material. The formulation process considers various parameters like drug-to-polymer ratio, stirring speed, and the concentration of Span 80, an emulsifying agent. These variables significantly affect the microparticles' characteristics, including their size, encapsulation efficiency, and drug release profile.
[008] The microparticles are designed to release Mebeverine hydrochloride in a controlled manner in the colon, maximizing its therapeutic efficacy while minimizing systemic side effects. The use of guargum, a natural polysaccharide, is particularly advantageous due to its biocompatibility and ability to be hydrolyzed by colonic microflora. However, controlling drug release from these highly hydrophilic materials poses a challenge, which this invention aims to address through careful optimization of the formulation parameters.
[009] The innovative aspect of this invention lies in the utilization of guargum, a natural polysaccharide, as the primary carrier for the drug. Guargum is particularly suitable for colon-targeted delivery due to its biocompatibility and susceptibility to hydrolysis by colonic microflora. This characteristic ensures that the drug is released in the colon where it can exert its therapeutic effect most efficiently.
[010] The formulation process of the microparticles involves the emulsion dehydration method, which includes critical process variables such as the drug-to-polymer ratio, stirring speed, and the concentration of Span 80, an emulsifying agent. These variables play a crucial role in determining the microparticles' characteristics like size, encapsulation efficiency, and drug release profile. For instance, a higher drug-to-polymer ratio tends to increase particle size and encapsulation efficiency. Similarly, the stirring speed during the preparation affects the size and surface characteristics of the microparticles, and the concentration of Span 80 influences the stability and uniformity of the emulsion.
[011] The research conducted on this invention extensively explores the optimization and characterization of these microparticles, aiming to strike a balance between sufficient drug encapsulation and controlled release. The ultimate goal is to achieve a formulation that not only ensures the effective delivery of Mebeverine hydrochloride to the colon but also minimizes systemic side effects.
[012] Overall, this invention represents a significant step forward in the treatment of IBS, offering a potentially more effective and targeted approach compared to existing treatments. The use of guargum as a carrier material not only enhances the drug's bioavailability but also leverages its natural properties for a safer and more efficient drug delivery system.
[013] The innovative aspect of this invention lies in the utilization of guargum, a natural polysaccharide, as the primary carrier for the drug. Guargum is particularly suitable for colon-targeted delivery due to its biocompatibility and susceptibility to hydrolysis by colonic microflora. This characteristic ensures that the drug is released in the colon where it can exert its therapeutic effect most efficiently.
[014] The formulation process of the microparticles involves the emulsion dehydration method, which includes critical process variables such as the drug-to-polymer ratio, stirring speed, and the concentration of Span 80, an emulsifying agent. These variables play a crucial role in determining the microparticles' characteristics like size, encapsulation efficiency, and drug release profile. For instance, a higher drug-to-polymer ratio tends to increase particle size and encapsulation efficiency. Similarly, the stirring speed during the preparation affects the size and surface characteristics of the microparticles, and the concentration of Span 80 influences the stability and uniformity of the emulsion.
[015] The research conducted on this invention extensively explores the optimization and characterization of these microparticles, aiming to strike a balance between sufficient drug encapsulation and controlled release. The ultimate goal is to achieve a formulation that not only ensures the effective delivery of Mebeverine hydrochloride to the colon but also minimizes systemic side effects.
[016] Overall, this invention represents a significant step forward in the treatment of IBS, offering a potentially more effective and targeted approach compared to existing treatments. The use of guargum as a carrier material not only enhances the drug's bioavailability but also leverages its natural properties for a safer and more efficient drug delivery system.
[017] In this respect, before explaining at least one object of the invention in detail, it is to be understood that the invention is not limited in its application to the details of set of rules and to the arrangements of the various models set forth in the following description or illustrated in the drawings. The invention is capable of other objects and of being practiced and carried out in various ways, according to the need of that industry. Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
[018] These together with other objects of the invention, along with the various features of novelty which characterize the invention, are pointed out with particularity in the disclosure. For a better understanding of the invention, its operating advantages and the specific objects attained by its uses, reference should be made to the accompanying drawings and descriptive matter in which there are illustrated preferred embodiments of the invention.
SUMMARY OF THE PRESENT INVENTION
[019] The proposed invention in your manuscript is focused on the development of guargum-based microparticles for the targeted delivery of Mebeverine hydrochloride, a drug used for treating irritable bowel syndrome (IBS). This innovative approach seeks to enhance the drug's oral bioavailability and ensure its specific absorption in the colon.
[020] The invention utilizes guargum, a natural polysaccharide, as the carrier material for Mebeverine hydrochloride. The selection of guargum is strategic due to its biocompatibility and susceptibility to hydrolysis by colonic microflora, ensuring the drug's release in the colon. The microparticles are prepared using the emulsion dehydration method, which involves critical process variables such as drug-to-polymer ratio, stirring speed, and the concentration of Span 80, an emulsifying agent. These factors significantly influence the microparticles' properties, including size, encapsulation efficiency, and drug release profile.
[021] The research systematically investigates the impact of these process variables on the optimization of the microparticles. For instance, a higher drug-to-polymer ratio tends to increase particle size and encapsulation efficiency, while the stirring speed affects the size and surface characteristics of the microparticles. The concentration of Span 80 influences the stability and uniformity of the emulsion, which is crucial for the successful formation of the microparticles.
[022] The study also focuses on the in vitro drug release behavior of these microparticles. The aim is to achieve a controlled release profile, ensuring that Mebeverine hydrochloride is released at the right site (the colon) and at the right time to maximize its therapeutic efficacy. The findings of this research could revolutionize the treatment of IBS, offering a more effective and targeted approach compared to existing treatments. By leveraging the properties of guargum, this invention presents a promising advancement in colon-targeted drug delivery systems, potentially improving therapeutic outcomes for IBS patients.
[023] In this respect, before explaining at least one object of the invention in detail, it is to be understood that the invention is not limited in its application to the details of set of rules and to the arrangements of the various models set forth in the following description or illustrated in the drawings. The invention is capable of other objects and of being practiced and carried out in various ways, according to the need of that industry. Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
[024] These together with other objects of the invention, along with the various features of novelty which characterize the invention, are pointed out with particularity in the disclosure. For a better understanding of the invention, its operating advantages and the specific objects attained by its uses, reference should be made to the accompanying drawings and descriptive matter in which there are illustrated preferred embodiments of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[025] When considering the following thorough explanation of the present invention, it will be easier to understand it and other objects than those mentioned above will become evident. Such description refers to the illustrations in the annex, wherein:
[026] FIG. 1, illustrates a general functional working diagram, in accordance with an embodiment of the present invention.
[027] FIG. 2, illustrates a concept of the functional flow diagram, in accordance with an embodiment of the present invention. in accordance with an embodiment of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[028] The following sections of this article will provide various embodiments of the current invention with references to the accompanying drawings, whereby the reference numbers utilised in the picture correspond to like elements throughout the description. However, this invention is not limited to the embodiment described here and may be embodied in several other ways. Instead, the embodiment is included to ensure that this disclosure is extensive and complete and that individuals of ordinary skill in the art are properly informed of the extent of the invention.
[029] Numerical values and ranges are given for many parts of the implementations discussed in the following thorough discussion. These numbers and ranges are merely to be used as examples and are not meant to restrict the claims' applicability. A variety of materials are also recognised as fitting for certain aspects of the implementations. These materials should only be used as examples and are not meant to restrict the application of the innovation.
[030] Referring now to the drawings, these are illustrated in FIG. 1&2, The proposed invention detailed in your manuscript focuses on the formulation and evaluation of guargum-based microparticles for the targeted delivery of Mebeverine hydrochloride, a drug used in the treatment of Irritable Bowel Syndrome (IBS). This novel approach employs guargum, a natural polysaccharide, as the carrier material for the controlled and site-specific release of the drug in the colon.
[031] The microparticles were prepared using the emulsion dehydration method, and the study extensively explores the effect of various process variables such as the drug-to-polymer ratio, stirring speed, and the concentration of Span 80, an emulsifying agent. These factors are crucial in determining the characteristics of the microparticles, including their size, encapsulation efficiency, and drug release profile.
[032] Key results from the study show that formulations with a drug-to-polymer ratio of 1:3, using a 1% w/v concentration of Span 80 at 500 rpm, were found to be optimal. These conditions resulted in the effective encapsulation and controlled release of Mebeverine hydrochloride. The optimized microparticles demonstrated high encapsulation efficiency, appropriate particle size, and a controlled drug release profile that is particularly suited for targeted delivery to the colon.
[033] The in vitro drug release studies indicated that these microparticles could successfully release Mebeverine hydrochloride in a controlled manner over a prolonged period, ensuring its therapeutic efficacy while minimizing systemic side effects. The study concludes that microencapsulation of Mebeverine hydrochloride in guargum-based microparticles represents a promising approach for achieving site-specific and controlled drug delivery in the colon, potentially improving therapeutic outcomes for patients with IBS.
[034] Key results indicate that the optimized microparticles, particularly the formulations GG3, GG6, and GG10, displayed desirable characteristics in terms of encapsulation efficiency, particle size, and drug release profile. The formulation process involved varying the drug-to-polymer ratio, stirring speed, and the concentration of Span 80, an emulsifying agent, to identify the most effective combination for drug delivery.
[035] The in vitro release studies of these microparticles revealed a controlled release profile of Mebeverine hydrochloride, with the drug being released specifically in the colon. This targeted delivery is crucial for maximizing the therapeutic efficacy of the drug while minimizing systemic side effects. The study's findings demonstrate the potential of guargum as a carrier for colon-specific drug delivery systems, highlighting its ability to enhance the bioavailability and efficacy of Mebeverine hydrochloride.
[036] Furthermore, the study conducted kinetic analysis of the drug release data, applying various mathematical models to understand the release mechanisms of the microparticles. The optimized formulations followed different release kinetics, which were crucial in understanding the drug release behavior from these guargum-based systems.
[037] In conclusion, the research presents a significant contribution to the field of targeted drug delivery. The successful development and optimization of guargum-based microparticles for Mebeverine hydrochloride delivery offer a promising approach for the treatment of IBS, showcasing the potential of natural polysaccharides in advanced pharmaceutical applications.
, Claims:1. A method for preparing guargum-based microparticles encapsulating Mebeverine hydrochloride for targeted drug delivery to the colon.
2. The method of claim 1, where the microparticles are prepared using an emulsion dehydration technique.
3. The method of claim 1 or 2, wherein the drug-to-polymer ratio in the microparticles is optimized for maximal encapsulation efficiency and controlled drug release.
4. A pharmaceutical composition comprising guargum-based microparticles encapsulating Mebeverine hydrochloride for oral administration.
5. The pharmaceutical composition of claim 4, wherein the microparticles release Mebeverine hydrochloride specifically in the colon.
6. The use of guargum as a carrier material in the preparation of microparticles for targeted drug delivery of Mebeverine hydrochloride.
7. A method for treating irritable bowel syndrome comprising administering an effective amount of the pharmaceutical composition of claim 4 to a patient in need thereof.
8. The method of claim 1, wherein the stirring speed and concentration of Span 80 are optimized during the preparation of the microparticles.
9. The pharmaceutical composition of claim 4, wherein the microparticles are characterized by a controlled drug release profile, ensuring the therapeutic efficacy of Mebeverine hydrochloride while minimizing systemic side effects.
10. A method for improving the oral bioavailability of Mebeverine hydrochloride in the treatment of irritable bowel syndrome, comprising administering the pharmaceutical composition of claim 4 to a patient.